These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16567729)

  • 21. Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets.
    Bao J; Gao S; Weng Y; Zhu J; Ye H; Zhang X
    Rev Neurol (Paris); 2019; 175(1-2):65-72. PubMed ID: 30293884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in therapy: prednisone for myasthenia gravis.
    Patten BM
    Tex Med; 1976 Dec; 72(12):54-5. PubMed ID: 1006553
    [No Abstract]   [Full Text] [Related]  

  • 23. [Eaton-Lambert syndrome. Long-term treatment with corticoids].
    Illa I; Pradas J; Vázquez J; Codina M
    Med Clin (Barc); 1986 May; 86(18):782. PubMed ID: 3736183
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis.
    Furukawa Y; Yoshikawa H; Iwasa K; Yamada M
    J Neuroimmunol; 2008 Mar; 195(1-2):108-15. PubMed ID: 18262659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.
    Zhang Y; Zhang M; Zhang L; Zhou S; Li W
    J Clin Neurosci; 2023 Oct; 116():93-98. PubMed ID: 37669613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Myasthenia gravis--treatment with prednisone].
    Spalek P; Lisý L
    Cesk Neurol Neurochir; 1982 Nov; 45(6):418-24. PubMed ID: 7151207
    [No Abstract]   [Full Text] [Related]  

  • 27. [The effect of prolonged treatment with prednisone on myasthenia gravis].
    Melamed E; Reches A; Silberberg R; Soffer D
    Harefuah; 1975 Jan; 88(2):65-7. PubMed ID: 1112555
    [No Abstract]   [Full Text] [Related]  

  • 28. Letter: Prednisone schedule for myasthenia gravis.
    McQuillen MP
    N Engl J Med; 1974 Mar; 290(11):631-2. PubMed ID: 4812507
    [No Abstract]   [Full Text] [Related]  

  • 29. Plasmapheresis as a guide for azathioprine therapy in prednisone-resistant myasthenia gravis.
    Rodnitzky RL; Bosch EP
    Muscle Nerve; 1981; 4(6):529-30. PubMed ID: 7311992
    [No Abstract]   [Full Text] [Related]  

  • 30. Results of an open trial of cyclosporine in a group of steroido-dependent myasthenic subjects.
    Antonini G; Bove R; Filippini C; Millefiorini M
    Clin Neurol Neurosurg; 1990; 92(4):317-21. PubMed ID: 1963821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone.
    Newsom-Davis J; Cutter G; Wolfe GI; Kaminski HJ; Jaretzki A; Minisman G; Aban I; Conwit R
    Ann N Y Acad Sci; 2008; 1132():344-7. PubMed ID: 18567886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tacrolimus monotherapy: a promising option for ocular myasthenia gravis.
    Yagi Y; Sanjo N; Yokota T; Mizusawa H
    Eur Neurol; 2013; 69(6):344-5. PubMed ID: 23549260
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
    Kim YH; Shin HY; Kim SM
    Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine.
    Gonzalez Molina M; Morales JM; Marcen R; Campistol JM; Oppenheimer F; Serón D; Gil-Vernet S; Capdevila L; Andrés A; Lampreave I; Del Castillo D; Cabello M; Burgos D; Valdés F; Anaya F; Escuín F; Arias M; Pallardó L; Bustamante J
    Transplant Proc; 2007 Sep; 39(7):2167-9. PubMed ID: 17889126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Large dose of prednisone in the treatment of the oculomuscular type of myasthenia gravis].
    Wang DC
    Zhonghua Yan Ke Za Zhi; 1984 Jul; 20(4):245-7. PubMed ID: 6439528
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
    Wang L; Zhang S; Xi J; Li W; Zhou L; Lu J; Lu J; Zhang T; Zhao C
    J Neurol; 2017 Nov; 264(11):2191-2200. PubMed ID: 28921038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
    Patel CG; Harmon M; Gohh RY; Akhlaghi F
    Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical therapeutic trial of cyclosporine in myasthenia gravis.
    Tindall RS; Phillips JT; Rollins JA; Wells L; Hall K
    Ann N Y Acad Sci; 1993 Jun; 681():539-51. PubMed ID: 8357194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Alternate day prednisone treatment in myasthenia].
    Mares A; Nisipeanu P; Lazăr T; Tudoran C
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1974; 19(5):395-401. PubMed ID: 4549646
    [No Abstract]   [Full Text] [Related]  

  • 40. Myasthenic crisis after the cessation of FK506 in a patient with myasthenia gravis.
    Konishi T; Sanada M; Takehana K
    J Neurol; 2004 Sep; 251(9):1154-5. PubMed ID: 15372266
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.